Synthesis of acalabrutinib loaded β-cyclodextrin-based metal–organic frameworks as a potential material for breast cancer therapy
The current investigation successfully synthesized a porous β-cyclodextrin metal organic frameworks (βCD-MOFs). Herein, acalabrutinib (ACB) loaded βCD-MOFs (ACB-MOF) was engineered to improve the efficacy of ACB for the treatment of breast cancer. The ACB-MOF exhibited a particle size (627 nm) PDI (...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Results in Chemistry |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211715625004953 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The current investigation successfully synthesized a porous β-cyclodextrin metal organic frameworks (βCD-MOFs). Herein, acalabrutinib (ACB) loaded βCD-MOFs (ACB-MOF) was engineered to improve the efficacy of ACB for the treatment of breast cancer. The ACB-MOF exhibited a particle size (627 nm) PDI (0.245) and EE (79.25 %), respectively. The developed ACB-MOF was characterized by fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), thermogravimetric analyzer (TGA) and nitrogen gas adsorption. In-vitro release studies exhibited an improved stability and release pattern for 24 h, with korsmayer-peppas kinetics model. ACB-MOF exhibited improved cytotoxicity and lowered IC50 (11.68 μg/mL) against MCF7 cells as compared to pure-ACB (25.01 μg/mL). The ACB-MOF also improve the level of apoptotic markers significantly (P53, caspase-3 and caspase-9), indicating a promising delivery for breast cancer. |
|---|---|
| ISSN: | 2211-7156 |